DWP
ABBV icon

Daymark Wealth Partners’s AbbVie ABBV Stock Holding History

Daymark Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.8M Buy
130,459
+45,770
+54% +$9.85M 0.8% 29
2026
Q1 		$18.4M Sell
84,689
-545
-0.6% -$121K 0.58% 39
2025
Q4 		$19.5M Buy
85,234
+96
+0.1% +$21.9K 0.62% 38
2025
Q3 		$19.7M Buy
85,138
+3,324
+4% +$677K 0.67% 37
2025
Q2 		$15.2M Buy
81,814
+2,276
+3% +$423K 0.58% 42
2025
Q1 		$16.7M Buy
79,538
+1,145
+1% +$223K 0.72% 34
2024
Q4 		$13.9M Sell
78,393
-807
-1% -$148K 0.59% 39
2024
Q3 		$15.6M Buy
79,200
+2,452
+3% +$458K 0.66% 37
2024
Q2 		$13.2M Buy
76,748
+33,981
+79% +$5.63M 0.6% 38
2024
Q1 		$7.79M Sell
42,767
-260
-0.6% -$44.8K 0.42% 55
2023
Q4 		$6.67M Sell
43,027
-4,008
-9% -$584K 0.41% 55
2023
Q3 		$7.01M Buy
47,035
+6,153
+15% +$903K 0.48% 49
2023
Q2 		$5.51M Buy
40,882
+5,394
+15% +$791K 0.41% 58
2023
Q1 		$5.66M Buy
35,488
+3,655
+11% +$559K 0.75% 27
2022
Q4 		$5.14M Buy
+31,833
New +$4.88M 0.91% 27

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Daymark Wealth Partners's ABBV Position: Q2 2026 in Review

Daymark Wealth Partners increased its AbbVie (ABBV) stake by 54% in Q2 2026, buying an estimated $9.85M and bringing the position to 130,459 shares worth $32.8M. The position accounts for 0.8% of the portfolio, ranked #29.

Daymark Wealth Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Daymark Wealth Partners held 130,459 shares of AbbVie worth $32.8M as of Q2 2026.
  • Daymark Wealth Partners bought 45,770 AbbVie shares in Q2 2026, an estimated $9.85M.
  • AbbVie made up 0.8% of Daymark Wealth Partners's portfolio in Q2 2026, its #29 holding.
  • Daymark Wealth Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.